Medibank Posts 6.7% Operating Profit Growth Amid Escalating Aggregator Costs
Australia's largest private health insurer grew policyholders 1.1% while confronting industry commission costs that nearly doubled to $200 million.
Strong Headline Growth Masks Strategic Tensions
Medibank Private Limited reported group operating profit of $813.5 million for fiscal 2026, up 6.7% year-over-year, as the health insurer navigated cost-of-living pressures and an increasingly competitive market (earnings call, 2026-08-19). The company serves approximately 6 million Australians across its Medibank and AHM brands.
Resident policyholder growth reached 1.1%, with the flagship Medibank brand doubling its growth rate to 0.6% and budget brand AHM expanding 2.4%. The company maintained a stable private health insurance gross margin of 17% and expense ratio of 8%, while delivering a fully franked final dividend of $0.109 per share.
Aggregator Commission Dispute Escalates
CEO David Koczkar used the earnings presentation to mount a pointed critique of the rapidly growing role of price comparison aggregators in Australia's health insurance market. Industry-wide commissions paid to aggregators have "almost doubled, reaching about $200 million" over two years, while aggregator sales grew 44% (earnings call, 2026-08-19).
Koczkar noted that in FY25, "about 3/4 of aggregator sales involved switching from one fund to the other and only 1/4 of these sales were new entrants to the private health system." He characterized upfront commissions as "opaque to the consumer" and warned of "commission-driven churn" that adds cost without corresponding value.
The company took concrete action in December, removing AHM from one aggregator panel "rather than signing up to terms that were unacceptable," acknowledging the decision would "have some volume impact in the short term" (earnings call, 2026-08-19).
Medibank Health Division Drives Diversification
The standout performance came from Medibank Health, which delivered record revenue growth of 31.3%. The division's Amplar Health network supported more than 5.3 million patient interactions, while the recent Better Medical acquisition created "one of Australia's largest multidisciplinary primary care networks" with 169 GP and medical clinics delivering over 4 million consultations (earnings call, 2026-08-19).
Community-based services supported 27,000 acute home health visits and saved 194,000 hospital bed days, as the company positions itself across the care continuum beyond traditional insurance.
Cost Management and Outlook
CFO Mark Rogers reported that expenses increased 5.4% to $690.2 million, driven by approximately 4% inflation, volume-related growth, and foundation investments. The company delivered $10 million in productivity savings during the year and targets another $10 million for FY27.
Non-recurring cyber incident costs declined, with Rogers projecting FY27 cyber-related expenses below $20 million, "primarily related to ongoing litigation" (earnings call, 2026-08-19).
In the non-resident business, student visa numbers normalized with lower-than-expected approvals, though the company secured preferred provider status for the Pacific Australia Labor Mobility scheme. Management expects the student portfolio to stabilize and non-resident operations to "deliver solid gross profit growth" in FY27 (earnings call, 2026-08-19).
MarginX data shows recent insider purchases by executives Everingham (25,000 shares), Hey (11,448 shares), and McIntyre (22,370 shares).
This article was generated by MarginX from the earnings call on 2026-08-19. It is not investment advice.